Michael McNulty Buys 24,561 Shares of Orthocell (ASX:OCC) Stock

Orthocell Limited (ASX:OCC) insider Michael McNulty acquired 24,561 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was purchased at an average price of A$1.14 per share, for a total transaction of A$27,974.98.

Orthocell Price Performance

The company has a debt-to-equity ratio of 15.22, a current ratio of 4.34 and a quick ratio of 5.07. The firm has a market capitalization of $375.52 million, a PE ratio of -42.23 and a beta of 1.16.

About Orthocell

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries.